Cosmo Pharmaceuticals Announces Hiring of Investor Relations and Leadership Change Manager


EQS-Ad-hoc: Cosmo Pharmaceuticals NV / Keyword (s): Miscellaneous
Cosmo Pharmaceuticals Announces Hiring of Investor Relations and Leadership Change Manager

30-Dec-2021 / 06:00 GMT / BST
Publication of an ad hoc announcement in accordance with art. 53 LR
The issuer is solely responsible for the content of this advertisement.

Ad hoc announcement in accordance with art. 53 LR

Dublin, Ireland – December 30, 2021: Cosmo Pharmaceuticals NV (SIX: COPN) (“Cosmo”) announced today that Ms. Hazel Winchester has been appointed as Head of Investor Relations and will take up her duties on January 10, 2022.

Ms. Winchester brings nearly two decades of investor relations experience. She is a seasoned IR professional who previously held various positions for a Swiss Medtech and more recently for a biopharmaceutical company listed on SIX. Prior to that, Ms. Winchester worked with various companies in Toronto, Canada, including one that went from small to large cap listed on the Toronto Stock Exchange and NYSE. She served on the board of directors of the Canadian Institute for Investor Relations (CIRI) and recently joined the board of directors of IR Club Switzerland.

Alessandro Della Chà, CEO of Cosmo, commented: ‘We have been figuring out how to fulfill this important role for some time and now believe we have found the right fit in Hazel. I hope it will help us to strengthen the relationship with investors at this very important moment in Cosmo’s history.‘.

Cosmo further announced that Mr. Stefano Selva, current CSO, had resigned from Cosmo for personal reasons with effect from December 31, 2021. Given the structure and organization of the R&D department, the Company does not envisage a immediately fill the position.

Annual results 2021 March 31, 2022
Annual General Meeting 2022 May 27, 2022
Half-year results 2022 July 29, 2022

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on the development and commercialization of products to treat certain gastrointestinal disorders and improve endoscopy quality measurements by facilitating the detection of colonic lesions. Cosmo develops and manufactures products that are distributed worldwide, including Lialda (R) and Uceris (R) / Cortiment (R). Cosmo has also developed medical devices for endoscopy and has partnered with Medtronic for the global distribution of GI Genius (TM), its artificial intelligence device, which uses artificial intelligence to help detect potential signs of Colon Cancer. Cosmo has licensed Aemcolo (R) to Red Hill Biopharma Ltd. for the US and licensed Relafalk (R) to Dr. Falk Gmbh for the EU and other countries. For more information about Cosmo and its products, please visit the Company’s website:

End of ad hoc announcement

Language: English
Society: Cosmo Pharmaceuticals SA
Riverside 2, Sir John Rogerson’s
Dublin 2 Dublin
Call: + 353 1 817 0370
E-mail: [email protected]
The Internet:
IS IN: NL0011832936
Registered: Swiss stock exchange SIX
EQS News ID: 1263320

End of the announcement EQS News Service

1263320 30-Dec-2021 GMT / BST

EQS 2021

Sales 2021 80.6 million
91.2 million
91.2 million
Net income 2021 52.8 million
59.8 million
59.8 million
Net cash position 2021 67.4 million
76.3 million
76.3 million
PER 2021 ratio 19.7x
Yield 2021
Capitalization 1,081 million
1,229 million
1,224 million
VE / Sales 2021 12.6x
VE / Sales 2022 11.8x
Number of employees 276
Free float 52.8%

Duration :

Period :

Cosmo Pharmaceuticals NV Technical Analysis Chart |  MarketScreener

Trends in technical analysis COSMO PHARMACEUTICALS NV

Short term Mid Road Long term
Tendencies Neutral Bearish Bearish

Evolution of the income statement

To sell

To buy

Average consensus TO BUY
Number of analysts 2
Last closing price

€ 64.21

Average price target

€ 97.02

Spread / Average target 51.1%

Source link


Comments are closed.